InvestorsHub Logo
Followers 1
Posts 69
Boards Moderated 0
Alias Born 03/31/2018

Re: None

Thursday, 05/17/2018 8:25:12 AM

Thursday, May 17, 2018 8:25:12 AM

Post# of 1450
Wonder if 5/18 Keynote Address Will Give Us Some Clues?

Presentation by Mike West coming tomorrow. I'm super curious to see what Agex is focusing on these days. I've noticed they've been saying iTR is going to be employed against cancer, which surprises me, as I think of iTR as building new healthy tissue, not destroying unwanted tissue. I guess maybe now that they think they understand the genes implicated with cell regeneration, it may somehow be easier to interfere with those genes in cancerous cells, rather than prompting normal cells to regenerate. That said, from the topics below, it looks like they are going to try and conquer both! I can't wait for this presentation. Agex has been very quiet on details of their work, and this may be the first detailed look at the path they are attempting on their various product lines. With the spinoff details due in the next 2 weeks, I think they are going to release the hounds here.

Here's today's announcement:

AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London

May 17, 2018 07:00 AM Eastern Daylight Time

ALAMEDA, Calif.--(BUSINESS WIRE)--AgeX Therapeutics, Inc., a subsidiary of BioTime, Inc. (NYSE American: BTX), today announced that the company’s Chief Executive Officer Michael D. West, Ph.D., who also serves as Co-CEO of BioTime, will deliver a keynote presentation at World Advanced Therapies & Regenerative Medicine Congress, May 16-18 in London.

“Aging and Regeneration: Commercial Implications of the New Science”

Taking place on Friday, May 18 at 12:30pm BST, Dr. West’s presentation, “Aging and Regeneration: Commercial Implications of the New Science” will address the following topics related to AgeX’s programs:

How can molecular and AI technologies help regenerate damaged tissue in humans?

What are the current challenges with induced tissue regeneration and how are we tackling them?

Combining pluripotent stem cell and iTR technology to form new company AgeX

A copy of Dr. West’s presentation will be available on the AgeX website.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LCTX News